Vertex Appoints Daniel Brennan to its Board of Directors
Key Highlights
- ➤Vertex (VRTX) appoints Daniel Brennan as an independent director
- ➤Vertex Board expands from 10 to 11 members
- ➤Brennan retired as Boston Scientific executive vice president and CFO last year
Expert Statements
Jeffrey Leiden, Executive Chairman of Vertex
“Dan’s extensive financial leadership experience and deep understanding of global healthcare businesses will bring an important perspective to the Vertex Board.”
Jeffrey Leiden, Executive Chairman of Vertex
“His experience navigating periods of high growth and strategic expansion will be especially valuable as Vertex continues to expand, diversify and invest in innovation so we can make a meaningful impact for many more patients.”
Daniel Brennan, Independent director of Vertex
“Vertex’s track record demonstrates what is possible when bold science is supported by a clear strategy and strong execution.”
Daniel Brennan, Independent director of Vertex
“I am honored to join the Board and look forward to helping the company extend its impact to more patients while sustaining the capabilities and investments needed for long-term success.”
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific’s Executive Vice President, Chief Financial Officer, where he had responsibility for all global finance functions and corporate business development.
“Dan’s extensive financial leadership experience and deep understanding of global healthcare businesses will bring an important perspective to the Vertex Board,” said Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex. “His experience navigating periods of high growth and strategic expansion will be especially valuable as Vertex continues to expand, diversify and invest in innovation so we can make a meaningful impact for many more patients.”
Get started
Create a free account to read the full story.